PARP2
Poly [ADP-ribose] polymerase 2
As of the edition of 20 October 2026, PARP2 (poly [ADP-ribose] polymerase 2, UniProt Q9UGN5) has 9 drugs tested at it and 15 companies on the list, 3 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UGN5
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 75
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Hormones; Skin and connective tissue; Digestive system; Lungs and airways; Blood and lymph
- Registered trials of its drugs
- 921
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Stopped | 3 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Olaparib | Marketed | Phase 4 | Ends 2028 |
| Niraparib | Marketed | Phase 4 | Ends 2031 |
| Talazoparib | Marketed | Phase 3 | Ends 2031 |
| Veliparib | Stopped | Phase 3 | none listed |
| Rucaparib | Marketed | Phase 3 | Ends 2031 |
| Pamiparib | Stopped | Phase 3 | none listed |
| Senaparib | Active | Phase 2 | none listed |
| 2X-121 | Active | Phase 2 | none listed |
| E-7016 | Stopped | Phase 2 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 6 |
| Engaged | 3 |
| Undetermined | 3 |
| Total on the list | 15 |
| Company | Route |
|---|---|
| GSK | Route B |
| AstraZeneca | Route B |
| Pfizer | Route B |
The other 12 companies at PARP2
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at PARP2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.